The appointment may be a response to activist pressure from the proxy contest. Monitor for further board changes, settlement announcements, or a definitive proxy statement. The expanded board with an industry veteran could stabilize governance but does not change fundamentals.
Price Chart
Executive Summary
Actuate Therapeutics appointed Martin H. Huber, MD, as an independent director, expanding the board from 7 to 8 members. The appointment is routine but comes 30 days after proxy fight materials (DEFA14A), suggesting it may be related to board composition negotiations. No financial impact.
Key Facts
- Martin H. Huber, MD, appointed to board effective May 1, 2026, filling a newly created seat (board expanded from 7 to 8 directors).
- Dr. Huber will serve as a Class III director until the 2027 annual meeting.
- Compensation includes 30,000 stock options (3-year vesting), $44,000 annual retainer, and $3,000 quarterly consulting fee for R&D advisory services.
- Dr. Huber previously served as CEO of Mersana Therapeutics (acquired by Day One Biopharmaceuticals) and held senior R&D roles at Xilio, TESARO, and Merck.
- The filing follows a DEFA14A (proxy fight materials) filed 30 days earlier, indicating an ongoing board contest.
Financial Impact
Immaterial; director compensation is standard and consulting fee is $12,000 per year.
Risk Factors
- Ongoing proxy contest may lead to further board turnover or distracting shareholder activism.
- Dr. Huber's consulting role (R&D advisory) introduces potential conflicts or additional compensation scrutiny.
- No financial guidance or operational updates provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-003515 |
| Document: actuate_ex9901.htm | 0001683168-26-003515 |
| Document: 0001683168-26-003515-index-headers.html | 0001683168-26-003515 |
| Document: 0001683168-26-003515-index.html | 0001683168-26-003515 |
| Document: 0001683168-26-003515.txt | 0001683168-26-003515 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | S-1/A | $0.5990 | awaiting T+5 | — | $0.4999 (+16.54%) |
Oct 14, 2026 12d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.4999 (−15.13%) |
Oct 6, 2026 19d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.4999 (+30.95%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.4999 (+48.46%) |
Jun 9, 2026 19w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.4999 (−75.13%) |
May 11, 2026 23w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.4999 (−82.70%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4999 (−83.28%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4999 (−83.28%) |
Apr 14, 2026 27w ago | Press Release | $2.08 $2.27 | ▲ +8.89% | ▲ +7.50% | $0.4999 (−75.97%) |
Mar 9, 2026 33w ago | Press Release | $2.95 $2.68 | ▼ −9.00% | ▼ −7.64% | $0.4999 (−83.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers